CA2141572A1 - Terfenadine Metabolites and Their Optically Pure Isomers for Treating Allergic Disorders - Google Patents

Terfenadine Metabolites and Their Optically Pure Isomers for Treating Allergic Disorders

Info

Publication number
CA2141572A1
CA2141572A1 CA 2141572 CA2141572A CA2141572A1 CA 2141572 A1 CA2141572 A1 CA 2141572A1 CA 2141572 CA2141572 CA 2141572 CA 2141572 A CA2141572 A CA 2141572A CA 2141572 A1 CA2141572 A1 CA 2141572A1
Authority
CA
Canada
Prior art keywords
optically pure
allergic disorders
pure isomers
treating allergic
terfenadine metabolites
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA 2141572
Other languages
French (fr)
Other versions
CA2141572C (en
Inventor
James W. Young
Nancy M. Gray
Raymond L. Woosley
Yiwang Chen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sunovion Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27129882&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2141572(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of CA2141572A1 publication Critical patent/CA2141572A1/en
Application granted granted Critical
Publication of CA2141572C publication Critical patent/CA2141572C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

A pharmaceutical composition comprising a compound of formula (I): wherein Z
is COOH, COOCH3 or CH2OH, or a pharmaceutically acceptable salt thereof, for use in an anti-histaminic treatment which does not induce any significant cardiac arrhythmia, comprising administering a therapeutically effective amount of a compound of formula (I) to a human patient.
CA002141572A 1992-08-03 1993-08-03 Terfenadine metabolites and their optically pure isomers for treating allergic disorders Expired - Lifetime CA2141572C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US92415692A 1992-08-03 1992-08-03
US92418292A 1992-08-03 1992-08-03
US07/924,156 1992-08-03
US07/924,182 1992-08-03
PCT/US1993/007260 WO1994003170A1 (en) 1992-08-03 1993-08-03 Terfenadine metabolites and their optically pure isomers for treating allergic disorders

Publications (2)

Publication Number Publication Date
CA2141572A1 true CA2141572A1 (en) 1994-02-17
CA2141572C CA2141572C (en) 2001-02-06

Family

ID=27129882

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002141572A Expired - Lifetime CA2141572C (en) 1992-08-03 1993-08-03 Terfenadine metabolites and their optically pure isomers for treating allergic disorders

Country Status (24)

Country Link
US (1) US5375693A (en)
EP (4) EP0815860B1 (en)
JP (6) JP3041954B2 (en)
KR (1) KR950702420A (en)
AT (3) ATE322899T1 (en)
AU (3) AU675240B2 (en)
BR (1) BR9306841A (en)
CA (1) CA2141572C (en)
CZ (1) CZ27495A3 (en)
DE (5) DE9320925U1 (en)
DK (3) DK0701443T4 (en)
ES (3) ES2257757T3 (en)
FI (1) FI950467A (en)
GB (1) GB2284351B (en)
GR (3) GR960300024T1 (en)
HK (1) HK1045806B (en)
HU (1) HU226242B1 (en)
NO (1) NO310644B1 (en)
PL (1) PL174373B1 (en)
PT (2) PT1214937E (en)
RO (1) RO116043B1 (en)
RU (1) RU2167657C2 (en)
SK (1) SK12495A3 (en)
WO (1) WO1994003170A1 (en)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69320952T2 (en) * 1992-05-11 1999-05-27 Merrell Pharma Inc USE OF TERFENADINE DERIVATIVES AS AN ANTIHISTAMINICS IN LIVER DISEASE PATIENTS
HU226242B1 (en) * 1992-08-03 2008-07-28 Sepracor Inc Use of terfenadin carboxylic acid, their salt and optically pure isomers for the preparation of pharmaceutical compositions, and pharmaceutical compositions against allergic disorders
US20020007068A1 (en) 1999-07-16 2002-01-17 D'ambra Thomas E. Piperidine derivatives and process for their production
DE69433346T2 (en) * 1993-06-24 2004-09-09 Albany Molecular Research, Inc. Preparation of compounds useful in the production of piperidine derivatives
WO1995010278A1 (en) * 1993-10-15 1995-04-20 Hoechst Marion Roussel, Inc. Treatment of allergic disorders with terfenadine carboxylate
US20030045722A1 (en) * 1994-05-18 2003-03-06 Henton Daniel R. Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof
CA2189007C (en) 1994-05-18 2004-03-02 Daniel R. Henton Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudormophs thereof
US5455049A (en) * 1995-01-04 1995-10-03 Ascent Pharmaceuticals, Inc. Terfenadine oral powder
ATE226819T1 (en) * 1995-02-28 2002-11-15 Aventis Pharma Inc MEDICINAL PREPARATIONS FOR PIPERIDINE CANOLDER DERIVATIVES
GB9513972D0 (en) * 1995-07-08 1995-09-06 Merck Sharp & Dohme Pharmaceutical compositions
US5906747A (en) * 1995-11-13 1999-05-25 Biosepra Inc. Separation of molecules from dilute solutions using composite chromatography media having high dynamic sorptive capacity at high flow rates
US6355656B1 (en) 1995-12-04 2002-03-12 Celgene Corporation Phenidate drug formulations having diminished abuse potential
US5733756A (en) * 1996-01-05 1998-03-31 Celgene Corporation Lactams and processes for stereoselective enrichment of lactams, amides, and esters
US6486177B2 (en) * 1995-12-04 2002-11-26 Celgene Corporation Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate
US5908850A (en) * 1995-12-04 1999-06-01 Celgene Corporation Method of treating attention deficit disorders with d-threo methylphenidate
US5922736A (en) * 1995-12-04 1999-07-13 Celegene Corporation Chronic, bolus administration of D-threo methylphenidate
US5837284A (en) 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
US6201124B1 (en) 1995-12-21 2001-03-13 Albany Molecular Research, Inc. Process for production of piperidine derivatives
US6153754A (en) 1995-12-21 2000-11-28 Albany Molecular Research, Inc. Process for production of piperidine derivatives
ES2124167B1 (en) * 1996-06-04 1999-09-16 Espanola Prod Quimicos NEW DERIVATIVES OF BENZMIDAZOLE WITH ANTIHISTAMINE ACTIVITY.
US5925761A (en) * 1997-02-04 1999-07-20 Sepracor Inc. Synthesis of terfenadine and derivatives
US6962997B1 (en) * 1997-05-22 2005-11-08 Celgene Corporation Process and intermediates for resolving piperidyl acetamide steroisomers
TR200000517T2 (en) * 1997-08-26 2000-08-21 Hoechst Marion Roussel, Inc. Pharmaceutical composition for the combination of piperidinoalkanol-Congestion reducer.
US6194431B1 (en) 1998-04-14 2001-02-27 Paul D. Rubin Methods and compositions using terfenadine metabolites in combination with leukotriene inhibitors
DE19913862C2 (en) * 1999-03-26 2003-04-10 Forschungszentrum Juelich Gmbh Process for the biocatalyzed conversion of poorly water-soluble substances
DE10007203A1 (en) * 2000-02-17 2001-08-23 Asta Medica Ag Composition for treating allergic and/or vasomotor rhinitis or allergic conjunctivitis by topical or oral administration, contains synergistic combination of non-sedating antihistamine and leukotriene antagonist
US6613907B2 (en) 2000-11-08 2003-09-02 Amr Technology, Inc. Process for the production of piperidine derivatives with microorganisms
PL366576A1 (en) * 2001-04-09 2005-02-07 Teva Pharmaceutical Industries Ltd. Polymorphs of fexofenadine hydrochloride
US20030021849A1 (en) * 2001-04-09 2003-01-30 Ben-Zion Dolitzky Polymorphs of fexofenadine hydrochloride
WO2003020274A1 (en) * 2001-08-30 2003-03-13 Aventis Pharmaceuticals Inc. Treatment of atopic dermatitis
EP1474392A1 (en) * 2002-06-10 2004-11-10 Teva Pharmaceutical Industries Ltd. Polymorphic form xvi of fexofenadine hydrochloride
US20050026890A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an antihistamine for treatment of asthma or chronic obstructive pulmonary disease
TW200517114A (en) 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
JP4515121B2 (en) 2004-03-15 2010-07-28 東芝テック株式会社 Wire dot printer head and wire dot printer
JP4473021B2 (en) 2004-03-22 2010-06-02 東芝テック株式会社 Nitride layer forming method, magnetic circuit forming member, armature, wire dot printer head, and wire dot printer
US20050239830A1 (en) * 2004-04-26 2005-10-27 Vikram Khetani Methods of diminishing co-abuse potential
KR20070007196A (en) * 2004-04-26 2007-01-12 테바 파마슈티컬 인더스트리즈 리미티드 Crystalline forms of fexofenadine hydrochloride and processes for their preparation
US7498345B2 (en) 2004-09-17 2009-03-03 Albany Molecular Research, Inc. Process for production of piperidine derivatives
US7498443B2 (en) 2004-09-17 2009-03-03 Albany Molecular Research, Inc. Process for production of carebastine
EP1685106A2 (en) * 2004-09-28 2006-08-02 Teva Pharmaceutical Industries, Inc. Fexofendadine crystal form and processes for its preparation thereof
BRPI0517166A (en) * 2004-12-09 2008-09-30 Celgene Corp use of d-threo methylphenidate or a salt thereof
KR20080065704A (en) 2005-11-09 2008-07-14 콤비네이토릭스, 인코포레이티드 Methods, compositions, and kits for the treatment of medical conditions
ES2534589T3 (en) * 2007-04-13 2015-04-24 Southern Research Institute Clomipramine as an antiangiogenic agent
US20090076080A1 (en) * 2007-09-19 2009-03-19 Protia, Llc Deuterium-enriched fexofenadine
US20150238473A1 (en) 2012-09-27 2015-08-27 University Of Rochester Methods and compositions for treating infection
NZ735777A (en) * 2015-03-26 2023-03-31 Jacqueline M Iversen Methods and compositions to inhibit symptoms associated with veisalgia
DE102017130361A1 (en) 2017-12-18 2019-07-04 Lsp Innovative Automotive Systems Gmbh Stator tooth and stator with good electrical insulation and at the same time very high thermal conductivity to increase the performance of electric motors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US880801A (en) † 1908-03-03 Harold Larsen Vibrator.
US922890A (en) † 1907-03-26 1909-05-25 Peder Joergen Hansen Stream-motor.
US4254129A (en) † 1979-04-10 1981-03-03 Richardson-Merrell Inc. Piperidine derivatives
US4552899A (en) † 1984-04-09 1985-11-12 Analgesic Associates Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs
US4829064A (en) † 1987-06-08 1989-05-09 Analgesic Associates Cough/cold mixtures comprising non-sedating antihistamine drugs
US4929605A (en) * 1987-10-07 1990-05-29 Merrell Dow Pharmaceuticals Inc. Pharmaceutical composition for piperidinoalkanol derivatives
US4996061A (en) † 1987-10-07 1991-02-26 Merrell Dow Pharmaceuticals Inc. Pharmaceutical composition for piperidinoalkanol-decongestant combination
HU226561B1 (en) * 1992-04-10 2009-04-28 Merrell Dow Pharma Process for preparation 4-diphenylmethyl piperidine derivatives and the novel intermediates thereof
DE69320952T2 (en) 1992-05-11 1999-05-27 Merrell Pharma Inc USE OF TERFENADINE DERIVATIVES AS AN ANTIHISTAMINICS IN LIVER DISEASE PATIENTS
HU226242B1 (en) * 1992-08-03 2008-07-28 Sepracor Inc Use of terfenadin carboxylic acid, their salt and optically pure isomers for the preparation of pharmaceutical compositions, and pharmaceutical compositions against allergic disorders
DE69433346T2 (en) * 1993-06-24 2004-09-09 Albany Molecular Research, Inc. Preparation of compounds useful in the production of piperidine derivatives
AU699559B2 (en) * 1993-06-25 1998-12-10 Aventisub Ii Inc. Novel intermediates for the preparation of antihistaminic piperidine derivatives
CA2128821A1 (en) * 1993-07-27 1995-01-28 Dilip J. Gole Freeze-dried pharmaceutical dosage form and process for separation thereof
CA2128820A1 (en) * 1993-07-27 1995-01-28 Walter G. Gowan, Jr. Rapidly disintegrating pharmaceutical dosage form and process for preparation thereof
WO1995010278A1 (en) * 1993-10-15 1995-04-20 Hoechst Marion Roussel, Inc. Treatment of allergic disorders with terfenadine carboxylate

Also Published As

Publication number Publication date
GR3035417T3 (en) 2001-05-31
HK1045806A1 (en) 2002-12-13
DE69334145T2 (en) 2008-01-24
HUT71889A (en) 1996-02-28
EP1214937A3 (en) 2002-10-30
GR3026530T3 (en) 1998-07-31
PL174373B1 (en) 1998-07-31
DK1214937T3 (en) 2007-09-17
EP0701443B2 (en) 2000-11-22
EP0815860A2 (en) 1998-01-07
ES2086270T3 (en) 1998-03-01
JP2000086515A (en) 2000-03-28
DK0815860T3 (en) 2006-08-14
RU2167657C2 (en) 2001-05-27
ATE363283T1 (en) 2007-06-15
HU226242B1 (en) 2008-07-28
DE69334008D1 (en) 2006-05-24
AU1842999A (en) 1999-04-29
ES2086270T1 (en) 1996-07-01
JP3288661B2 (en) 2002-06-04
CA2141572C (en) 2001-02-06
PT1214937E (en) 2007-07-25
FI950467A (en) 1995-03-31
EP0815860B1 (en) 2006-04-12
JP3288662B2 (en) 2002-06-04
ES2257757T3 (en) 2006-08-01
JP3041954B2 (en) 2000-05-15
EP1688142A1 (en) 2006-08-09
GR960300024T1 (en) 1996-05-31
GB9502183D0 (en) 1995-03-22
RU95107881A (en) 1996-11-27
JPH08500348A (en) 1996-01-16
DE69334145D1 (en) 2007-07-12
PL307339A1 (en) 1995-05-15
PT815860E (en) 2006-08-31
ATE322899T1 (en) 2006-04-15
EP0815860A3 (en) 1998-01-14
GB2284351B (en) 1996-11-27
HK1045806B (en) 2008-03-14
KR950702420A (en) 1995-07-29
EP0701443B1 (en) 1998-01-21
CZ27495A3 (en) 1996-09-11
RO116043B1 (en) 2000-10-30
DK0701443T4 (en) 2000-12-18
DE69316660T2 (en) 1998-05-07
AU675240B2 (en) 1997-01-30
JP2000086513A (en) 2000-03-28
NO950374D0 (en) 1995-02-01
NO310644B1 (en) 2001-08-06
ES2086270T5 (en) 2001-02-01
EP0701443A1 (en) 1996-03-20
DE69316660T3 (en) 2001-04-05
SK12495A3 (en) 1997-01-08
EP1214937A2 (en) 2002-06-19
ATE162399T1 (en) 1998-02-15
JP2000086512A (en) 2000-03-28
AU4798693A (en) 1994-03-03
DE701443T1 (en) 1997-01-30
ES2284740T3 (en) 2007-11-16
EP1214937B1 (en) 2007-05-30
JP3037697B2 (en) 2000-04-24
AU7182296A (en) 1997-01-30
DE9320925U1 (en) 1995-08-31
BR9306841A (en) 1998-12-08
NO950374L (en) 1995-03-29
JP3288660B2 (en) 2002-06-04
DE69316660D1 (en) 1998-02-26
US5375693A (en) 1994-12-27
JP2000086516A (en) 2000-03-28
WO1994003170A1 (en) 1994-02-17
HU9500313D0 (en) 1995-03-28
DE69334008T2 (en) 2006-10-19
FI950467A0 (en) 1995-02-02
JP2000086514A (en) 2000-03-28
DK0701443T3 (en) 1998-02-09
GB2284351A (en) 1995-06-07

Similar Documents

Publication Publication Date Title
CA2141572A1 (en) Terfenadine Metabolites and Their Optically Pure Isomers for Treating Allergic Disorders
CA2143610A1 (en) Use of norastemizole for the treatment of allergic disorders

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20130803